Enhanced Cardioprotection Against Ischemia-Reperfusion Injury with Combining Sildenafil with Low-Dose Atorvastatin
Authors:
- 23 January 2006
- journal article
- research article
- Published by Springer Nature in Cardiovascular Drugs and Therapy
- Vol. 20 (1) , 27-36
Abstract
Purpose: Both ATV and SL reduce myocardial infarct size (IS) by enhancing expression and activity of NOS isoforms. We investigated whether atorvastatin (ATV) and sildenafil (SL) have synergistic effects on myocardial infarct size (IS) reduction and enhancing nitric oxide synthase (NOS) expression. Method: Rats were randomized to nine groups: ATV-1 (1 mg/kg/d); ATV-10 (10 mg/kg/d); SL-0.7 (0.7 mg/kg); SL-1 (1 mg/kg); ATV-1 + SL-0.7; water alone (controls); 1400W (iNOS inhibitor; 1 mg/kg); ATV-10 + 1400W; and ATV-1 + SL-0.7 + 1400W. ATV was administered orally for 3 days. SL was administered intraperitoneally 18 h before surgery and 1400W intravenously 15 min before surgery. Rats either underwent 30 min ischemia-4 h reperfusion or the hearts were explanted for immunoblotting and enzyme activity tests without being exposed to ischemia. Results: IS (% risk area, mean ± SEM) was smaller in the ATV-10 (13 ± 1%), SL-1 (11 ± 2%), SL-0.7 (18 ± 2%) and ATV-1 + SL-0.7 (9 ± 1%) groups as compared with controls (34 ± 3%; P < 0.001), whereas ATV-1 had no effect (29 ± 2%). ATV-1 + SL-0.7 (9 ± 1%) reduced IS more than SL-0.7 alone (p = 0.012). 1400W abrogated the protective effect of ATV-10 (35 ± 3%) and ATV-1 + SL-0.7 (34 ± 1%). SL-0.7 and ATV-10 increased phosphorylated endothelial (P-eNOS; 210 ± 2.5% and 220 ± 8%) and inducible (iNOS; 151 ± 1% and 154 ± 1%) NOS expression, whereas ATV-1 did not. These changes were significantly enhanced by ATV-1 + SL-0.7 (P-eNOS, 256 ± 2%, iNOS 195 ± 1%). SL-1 increased P-eNOS (311 ± 22%) and iNOS (185 ± 1%) concentrations. Conclusions: Combining low-dose ATV with SL augments the IS limiting effects through enhanced P-eNOS and iNOS expression.Keywords
This publication has 48 references indexed in Scilit:
- Prostaglandins mediate the cardioprotective effects of atorvastatin against ischemia?reperfusion injuryCardiovascular Research, 2005
- Ischemic preconditioning: emerging evidence, controversy, and translational trialsInternational Journal of Cardiology, 2004
- RETRACTED: Statin blocks Rho/Rho-kinase signalling and disrupts the actin cytoskeleton: relationship to enhancement of LPS-mediated nitric oxide synthesis in vascular smooth muscle cellsBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2004
- Reduction in cardiovascular events after vascular surgery with atorvastatin: a randomized trialJournal of Vascular Surgery, 2004
- Protein kinase C plays an essential role in sildenafil-induced cardioprotection in rabbitsAmerican Journal of Physiology-Heart and Circulatory Physiology, 2004
- Statins Are Associated With a Reduced Incidence of Perioperative Mortality in Patients Undergoing Major Noncardiac Vascular SurgeryCirculation, 2003
- HMG‐CoA reductase inhibition protects the diabetic myocardium from ischemia‐reperfusion injuryThe FASEB Journal, 2001
- Mevastatin, an HMG-CoA Reductase Inhibitor, Reduces Stroke Damage and Upregulates Endothelial Nitric Oxide Synthase in MiceStroke, 2001
- Atorvastatin Upregulates Type III Nitric Oxide Synthase in Thrombocytes, Decreases Platelet Activation, and Protects From Cerebral Ischemia in Normocholesterolemic MiceStroke, 2000
- Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells.Journal of Clinical Investigation, 1998